Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism SSTR4 agonists(Somatostatin receptor 4 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetic peripheral neuropathic pain | Phase 2 | US | 06 May 2021 | |
Diabetic peripheral neuropathic pain | Preclinical | PR | 06 May 2021 | |
Chronic Pain | Preclinical | PR | 12 Nov 2020 | |
Chronic Pain | Preclinical | US | 12 Nov 2020 | |
Low Back Pain | Discovery | PR | 20 May 2021 | |
Low Back Pain | Discovery | US | 20 May 2021 | |
Osteoarthritis | Discovery | US | 12 Nov 2020 | |
Osteoarthritis | Discovery | PR | 12 Nov 2020 |
Phase 2 | 202 | (LY3556050 600 mg) | iwvlluneeh(xebucfjuit) = fwghirtcly rtadmrkcsg (bctqvwfvnu, iejbexbqxi - luufilkmbj) View more | - | 02 Nov 2023 | ||
Placebo (Placebo) | iwvlluneeh(xebucfjuit) = mfiytxzqka rtadmrkcsg (bctqvwfvnu, cesjihzjxh - fuafzfcpuo) View more | ||||||
Phase 2 | 68 | Placebo | coietfzjjy(eswwlyzjtk) = tzzeglelgd iddeeqnogt (clthjozbxb, jwoosyrdbv - xwvdlinbfw) View more | - | 02 Nov 2023 | ||
Phase 2 | 153 | Placebo | (upybtniidl) = zmjpibngmf talqtxckyc (ipfwudolkk, hxrvyhabky - nclvaksdbz) View more | - | 02 Nov 2023 |